iRadimed (NASDAQ:IRMD) Stock Price Passes Above 50 Day Moving Average – Should You Sell?

iRadimed Corporation (NASDAQ:IRMD)’s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $98.67 and traded as high as $104.17. iRadimed shares last traded at $100.63, with a volume of 48,779 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Roth Mkm reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Finally, Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Trading Up 0.8%

The company has a market capitalization of $1.28 billion, a P/E ratio of 57.50 and a beta of 1.11. The company’s 50 day moving average is $98.67 and its 200-day moving average is $84.88.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.85%. The business had revenue of $22.69 million for the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Analysts predict that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Monday, February 23rd will be paid a dividend of $0.20 per share. The ex-dividend date is Monday, February 23rd. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. iRadimed’s dividend payout ratio (DPR) is presently 38.86%.

Insiders Place Their Bets

In other iRadimed news, CFO John Glenn sold 15,000 shares of iRadimed stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the transaction, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. The trade was a 67.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $100.65, for a total transaction of $503,250.00. Following the completion of the transaction, the chief executive officer owned 2,262,500 shares in the company, valued at approximately $227,720,625. This represents a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 50,000 shares of company stock worth $4,859,950. Insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRMD. Royal Bank of Canada increased its holdings in shares of iRadimed by 14.7% in the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after purchasing an additional 3,307 shares in the last quarter. AQR Capital Management LLC increased its holdings in iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after buying an additional 1,108 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after buying an additional 234 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in iRadimed by 8,568.5% during the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock valued at $591,000 after acquiring an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of iRadimed by 1.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock valued at $8,889,000 after acquiring an additional 1,821 shares during the last quarter. 92.34% of the stock is owned by institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.